NCT07558395

Brief Summary

Evaluate the efficiency of audiovisual stimulation in virtual reality for improving the visual perception of children, adolescents, and young adults with hemianopia resulting from pediatric brain tumors. These individuals can lose up to 50% of their visual field, significantly impacting their independence, mobility, and daily lives.

Trial Health

70
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
40mo left

Started May 2026

Longer than P75 for not_applicable

Geographic Reach
7 countries

8 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 25, 2025

Completed
5 months until next milestone

First Posted

Study publicly available on registry

April 30, 2026

Completed
15 days until next milestone

Study Start

First participant enrolled

May 15, 2026

Expected
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2029

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2029

Last Updated

April 30, 2026

Status Verified

April 1, 2026

Enrollment Period

3.3 years

First QC Date

November 25, 2025

Last Update Submit

April 23, 2026

Conditions

Keywords

brain tumorpediatricvisual rehabilitationvirtual reality

Outcome Measures

Primary Outcomes (1)

  • Visual field perimetry measured using the Esterman binocular field test

    Increase at least 3 points in the number of points perceived in the blind field at the Esterman binocular field test after intervention (8 weeks) when compared to baseline and between control and interventional group.

    From enrollment to the end of follow up period at 6 months

Secondary Outcomes (2)

  • Participant-reported a vision impairment specific quality of life questionnaire: Impact of Vision Impairment Questionnaire (IVI).

    From enrollment to the end of follow up period at 6 months

  • Reading speed - Minnesota Low Vision Reading (MNREAD) test

    From enrollment to the end of follow up period at 6 months

Study Arms (2)

Control

OTHER

Standard of care for the first 8 weeks then visual stimulation for the following 8 weeks

Device: Visual StimulationOther: standard of care

Intervention

OTHER

Visual stimulation for the first 8 weeks then standard of care for the following 8 weeks

Device: Visual StimulationOther: standard of care

Interventions

Our audiovisual stimulation procedure IVR, called 3D-MOT, was encoded using the the 3D Unity programming platform and deployed in HMDs with built-in head/eye tracking. We implemented the multiple object tracking (MOT) paradigm, developed in the 80's to study visual attention in humans, and added correlated spatial sound.

ControlIntervention

During this phase, the patients will be at home without a headset and will not be exposed to an audio-visual stimulation task in virtual reality.

ControlIntervention

Eligibility Criteria

Age10 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Male and Female
  • years old
  • Diagnosed hemianopsia (\>12 months)
  • History of diagnosis brain tumour
  • Being stable for the tumour for \> 6 months (either on therapy or not)
  • Visual acuity ≤ 0.7 LogMAR
  • Ability to follow the visual and auditory stimuli and training instructions
  • Home WiFi access
  • Ability to attend all on site visits
  • Affiliation to the Social Security or beneficiary of such social protection

You may not qualify if:

  • Age\< 10 years old of \> 40 years old
  • Ocular disease
  • Inability to perform during testing or training
  • History of vertigo
  • Prior vision rehabilitation interventions
  • Recreational or medicinal consumption of psychoactive drugs
  • Persons under court protection
  • Interpupillary distance \< 54mm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Department of Paediatric and adolescents medicine, Medical University

Vienna, Austria

Location

Paediatrics and Adolescents Medicine, University Hospital

Copenhagen, Denmark

Location

Hôpital de Hautepierre

Strasbourg, France

Location

Institute of Tumour, department of haematology and Oncohaematology paediatric

Milan, Italy

Location

Paediatric Haematology, University Hospital

Padova, Italy

Location

Princess Maxima Centre for Paediatric Oncology

Utrecht, Netherlands

Location

Paediatric Oncology, San Joan de Deu

Barcelona, Spain

Location

Great Ormond Street Hospital for Children

London, United Kingdom

Location

MeSH Terms

Conditions

HemianopsiaBrain Neoplasms

Interventions

Photic StimulationStandard of Care

Condition Hierarchy (Ancestors)

Vision DisordersSensation DisordersNeurologic ManifestationsNervous System DiseasesBlindnessEye DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System Diseases

Intervention Hierarchy (Ancestors)

Physical StimulationInvestigative TechniquesQuality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: We will perform a phase IIb, single blind (to assessor), prospective, randomized, controlled, multicentric, delayed-start, parallel-group study.
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 25, 2025

First Posted

April 30, 2026

Study Start (Estimated)

May 15, 2026

Primary Completion (Estimated)

September 1, 2029

Study Completion (Estimated)

September 1, 2029

Last Updated

April 30, 2026

Record last verified: 2026-04

Locations